ImmunoPrecise advances dengue vaccine program to manufacturing phase

AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), a $125 million market cap biotech company whose stock has surged over 560% year-to-date, announced Wednesday it has progressed to the manufacturing phase for its universal dengue vaccine candidate, moving the project from artificial intelligence discovery to pre-clinical testing.

The company will manufacture the validated dengue epitope for use in immunization studies using a rabbit model at its Canadian facility. These tests aim to evaluate whether the vaccine candidate can generate monoclonal antibody responses against the virus. With annual revenue of $17.79 million and a healthy gross profit margin of 55.25%, ImmunoPrecise maintains strong operational capabilities despite not yet achieving profitability, according to InvestingPro data.

According to the company’s press release, the vaccine target is a discontiguous epitope that is conserved across all four dengue virus serotypes, which was identified using IPA’s LENSai platform powered by HYFT technology.

"We’ve shown that HYFT technology can identify vaccine targets that others miss," said Dr. Jennifer Bath, CEO of ImmunoPrecise, in the company statement.

The company reported that in silico screening has already confirmed the epitope’s potential for immune activation, structural stability, and safety against host proteomes.

ImmunoPrecise describes its approach as combining AI-driven discovery with in-house laboratory validation, creating what it calls an "in silico-to-in vivo workflow" that could potentially be applied to other infectious diseases beyond dengue.

The announcement represents the next step in IPA’s dengue vaccine development program following its June announcement about the discovery and validation of the conserved dengue epitope.

ImmunoPrecise Antibodies describes itself as a biotherapeutics company focused on developing next-generation biologics through its proprietary technologies and scientific expertise. The company is scheduled to report its next earnings in 16 days, which investors can analyze using InvestingPro’s comprehensive research tools and additional ProTips. For deeper insights into IPA’s valuation and growth potential, access the full Pro Research Report, available exclusively to InvestingPro subscribers.

In other recent news, ImmunoPrecise Antibodies Ltd. reported record revenue in the fourth quarter of 2025, totaling $7 million. The company also experienced a significant improvement in its gross margin, which increased to 64% from 48% the previous year. In a strategic move, ImmunoPrecise Antibodies sold its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V., to AVS Bio for $12 million, resulting in $11.7 million in net proceeds. This transaction reflects the company’s ongoing efforts to optimize its operations. Despite these financial achievements, the company noted a decline in its stock price, unrelated to the earnings results. The sale of the subsidiary aligns with ImmunoPrecise’s broader strategic advancements and operational efficiencies. AVS Bio, a portfolio company of Arlington Capital Partners, will now manage the acquired subsidiary. These developments highlight ImmunoPrecise’s focus on refining its business strategy and financial health.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.